The Otitis Media drugs in development market research report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Otitis Media. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Otitis Media and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Otitis Media by 17 companies/universities/institutes. The top development phase for Otitis Media is preclinical with 12 drugs in that stage. The Otitis Media pipeline has 18 drugs in development by companies and two by universities/ institutes. Some of the companies in the Otitis Media pipeline products market are: Chengdu Olymvax Biopharmaceuticals, Vaxcyte and Clarametyx Biosciences.
The key targets in the Otitis Media pipeline products market include DNA Gyrase, DNA Topoisomerase IV, and 23S Ribosomal RNA.
The key mechanisms of action in the Otitis Media pipeline product include DNA Topoisomerase IV Inhibitor with two drugs in Pre-Registration. The Otitis Media pipeline products include nine routes of administration with the top ROA being Intramuscular and five key molecule types in the Otitis Media pipeline products market including Conjugate Vaccine, and Small Molecule.
Otitis Media overview
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache, and loss of appetite. Risk factors include age, seasonal factors, and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.
For a complete picture of Otitis Media’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
